Alkem Laboratories (Alkem) hereby announces to launch of a unique patented technology for the treatment of Diabetic Foot Ulcer (DFU) in India. The solution would be based on disruptive 4D bioprinting
India currently has approximately 77 mn diabetes patients, the second-highest in the world. A diabetic foot ulcer is one of the most significant and devastating complications of diabetes and is defined as a foot affected by ulceration that is associated with neuropathy and/or peripheral arterial disease of the lower limb in a patient with diabetes.
Approximately, 12-15% with diabetes suffer from DFU at least once in a lifetime. 5–24% of them will finally lead to limb amputation within 6–18 months after the first evaluation. The risk of foot ulceration and limb amputation increases with age and the duration of diabetes. Alkem has collaborated with Rokit Healthcare to commercialize the technology in India to help reduce amputation amongst DFU patients considering the negative impact of amputation on a patient’s quality of life and the associated economic burden on healthcare system.
Sandeep Singh, managing director, Alkem Laboratories, stated, “In India, Diabetes is one of the major healthcare challenges. The challenge in itself is so huge that diabetic foot ulcers often get ignored. Approximately 1 lac people have to undergo amputation every year and compromise on their
Adding further, Sandeep asserted, “Alkem, over the years, has always been at the forefront in delivering high-quality patient care, through its innovation and patient-centric initiatives.”